With a cardiology perspective spanning 50 years, Professor Lars Wallentin offers insight to the development of low-dose aspirin as a treatment for heart disease. Along with colleagues at Uppsala University Hospital and others across Sweden he set up the Research Group on Instability in Coronary Artery Disease (RISC) study, which showed that the rate of new myocardial infarction was halved in a randomised trial group treated with low-dose aspirin. In conversation with health journalist Pennie Taylor, the recipient of the IAF Senior Science Award 2020 describes the development of clinical trial methodology, that breakthrough, and reflects on the progress that followed.
Have something to say about aspirin?
Please fill in the form below and we will contact you with further information.